Do Not Start the MRA
If a patient's serum potassium is 5.0 mEq/L or higher, you should not initiate a mineralocorticoid receptor antagonist (MRA). 1
Clear Guideline Threshold
The 2022 AHA/ACC/HFSA Heart Failure Guidelines explicitly state that MRAs are recommended only when serum potassium is <5.0 mEq/L 1. This is a Class 1, Level A recommendation—the strongest evidence-based guidance available. The guideline further emphasizes that hyperkalemia risk is particularly elevated when MRA is initiated at serum potassium ≥5.0 mEq/L 1.
What To Do Instead
Step 1: Address the elevated potassium first
- Identify and eliminate reversible causes of hyperkalemia:
- Review medications (NSAIDs, potassium supplements, trimethoprim-containing antibiotics)
- Assess for acute kidney injury or dehydration
- Check for metabolic acidosis
Step 2: Lower potassium below 5.0 mEq/L
- Initiate dietary potassium restriction with dietitian guidance 2
- Consider loop or thiazide diuretics if volume overloaded
- Optimize other GDMT that may help (SGLT2 inhibitors can have modest potassium-lowering effects)
- Consider potassium binders (patiromer or sodium zirconium cyclosilicate) if needed, though their role in facilitating MRA initiation remains uncertain 1
Step 3: Recheck potassium
- Once potassium is consistently <5.0 mEq/L, you can safely initiate the MRA
- Start at 25 mg daily (or 12.5 mg if eGFR 31-49 mL/min/1.73 m²) 1
Step 4: Monitor closely after initiation
- Check potassium and creatinine at approximately 1 week, then 4 weeks, then every 6 months 1
- More frequent monitoring if clinical instability
Critical Safety Considerations
The guidelines are unequivocal: MRAs should be discontinued if serum potassium cannot be maintained <5.5 mEq/L (Class 3: Harm recommendation) 1. Starting an MRA at potassium 5.0 mEq/L places the patient at immediate risk of life-threatening hyperkalemia, particularly given that:
- MRAs decrease renal potassium excretion
- Coadministration with ACE inhibitors or ARBs (which most HF patients receive) further increases hyperkalemia risk 1
- Real-world observational data show worse outcomes with MRA use when safety protocols aren't followed 1
The Mortality Trade-Off
While MRAs provide substantial mortality benefit in HFrEF (high-value therapy with cost per QALY <$1000) 1, this benefit evaporates—and reverses to harm—when hyperkalemia develops. Even mild hyperkalemia (>5.0 mEq/L) leads to MRA discontinuation in real-world practice 3, 4, and severe hyperkalemia can cause fatal arrhythmias.
The correct approach is to optimize potassium first, then safely initiate the MRA—not to start the MRA and hope the potassium doesn't rise further. This protects both immediate safety (avoiding life-threatening hyperkalemia) and long-term outcomes (enabling sustained MRA therapy).